Orotta College of Medicine and Health Sciences, Asmara, Eritrea.
Asmara College of Health Sciences, Asmara, Eritrea.
PLoS One. 2022 Jul 1;17(7):e0270838. doi: 10.1371/journal.pone.0270838. eCollection 2022.
Though the initiation of Highly Active Antiretroviral Therapy (HAART) has led to decreased HIV/AIDS related mortality, the regimen has been reported to be associated with lipid toxicities. Baseline data on such disturbances are required to induce countrywide interventional HIV/AIDS programs. The aim of this study was to determine the frequency and risks of dyslipidemia in HIV patients on HAART medication in Eritrea.
A cross sectional study was conducted on HIV/AIDS patients in two national referral hospitals in Asmara, Eritrea. A structured questionnaire was used to collect demographic data and blood sample was taken for analyses of lipid profile tests. Data was analyzed using chi-square test, Post Hoc and logistic regression in SPSS software.
The study included 382 participants of whom 256(67%) were females. Their median age, CD4+ T cell count (cell/microliter) and duration of HAART (years) was 45(IQR: 38-51), 434(IQR: 294-583) & 5(IQR: 3-5) respectively. The prevalence of dyslipidemia was 331(86.6%). Increased Low Density Lipoprotein-C (LDL-C) 213(55.8%) was the predominant abnormality. Abacavir was significantly related with highest means of triglycerides (TG) (228.17 ± 193.81) and lowest means of High Density Lipoprotein (HDL-C) (46.94 ± 12.02). Females had substantially higher proportions of TG (aOR = 2.89, 95% CI: 1.65-5.05) and TC/HDL ratio (aOR = 2.33, 95% CI: 1.40-3.87) and low HDL-C (aOR = 2.16, 95% CI: 1.34-3.48). Increased age was related with increased pro-atherogenic lipid parameters. High LDL-C was more infrequent in non-smokers (aOR = 0.028, 95% CI: 0.12-0.69).
The study showed a high prevalence of dyslipidemia in HIV-patients receiving HAART in Eritrea. Sex, age and smoking practice were among key factors associated with dyslipidemia. The necessity to assess lipid profiles and other cardiovascular risk factors before initiation of HAART treatment and continuous monitoring during therapy is mandatory.
尽管高效抗逆转录病毒疗法（HAART）的启动降低了与艾滋病毒/艾滋病相关的死亡率，但该方案已被报道与脂质毒性有关。需要有关此类干扰的基线数据来启动全国性的艾滋病毒/艾滋病干预项目。本研究的目的是确定厄立特里亚接受 HAART 治疗的艾滋病毒患者中血脂异常的频率和风险。
在厄立特里亚阿斯马拉的两家国家转诊医院对艾滋病毒/艾滋病患者进行了横断面研究。使用结构化问卷收集人口统计学数据，并采集血样进行血脂谱检测。使用 SPSS 软件中的卡方检验、事后检验和逻辑回归进行数据分析。
该研究包括 382 名参与者，其中 256 名（67%）为女性。他们的中位年龄、CD4+T 细胞计数（细胞/微升）和 HAART 持续时间（年）分别为 45（IQR：38-51）、434（IQR：294-583）和 5（IQR：3-5）。血脂异常的患病率为 331 例（86.6%）。升高的低密度脂蛋白胆固醇（LDL-C）213 例（55.8%）是最常见的异常。阿巴卡韦与最高甘油三酯（TG）均值（228.17 ± 193.81）和最低高密度脂蛋白（HDL-C）均值（46.94 ± 12.02）显著相关。女性的 TG（aOR = 2.89，95%CI：1.65-5.05）和 TC/HDL 比值（aOR = 2.33，95%CI：1.40-3.87）以及低 HDL-C（aOR = 2.16，95%CI：1.34-3.48）的比例显著更高。年龄增加与致动脉粥样硬化脂质参数增加有关。非吸烟者的高 LDL-C 更为罕见（aOR = 0.028，95%CI：0.12-0.69）。
本研究表明，厄立特里亚接受 HAART 治疗的艾滋病毒患者血脂异常患病率较高。性别、年龄和吸烟习惯是与血脂异常相关的关键因素之一。在开始 HAART 治疗之前必须评估血脂谱和其他心血管危险因素，并在治疗期间进行持续监测。
